Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
A legfontosabb adatok
- Hol
- Copenhagen, Odense és Roskilde (Dánia)Mind a 3 helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akik myeloma multiplexben vagy akut leukémiában szenvednek, és Daratumumab vagy Cytarabine kezelést kapnak. Azt vizsgálja, miért utasítják el vagy miért nem kaphatják egyes betegek a kezelést otthon.
- Életkor
- 18 és 100 év között
- Nem
- Nemtől függetlenül bárki részt vehet.
- A betegség stádiuma
- Myeloma multiplex vagy akut leukémia.
- Korábbi kezelés
- Daratumumab vagy Cytarabine kezelést kap.
A részvétel fő kizáró okai
- Demencia
- Pszichotikus zavarok
- Egyéb, a részvételt korlátozó kognitív zavarok
Gépi kiolvasás: 2026. november 9.
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 100 év között vagy?
Forrás: NCT07634263: ki vehet részt
Helyszínek itt: Dánia
- Copenhagen University Hospital, RigshospitaletCopenhagen, DániaNo longer taking part
- Odense University HospitalOdense, DániaNo longer taking part
- Sjællands Universitets HospitalRoskilde, DániaNo longer taking part
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
A vizsgálat adatai
- Ki végzi
- Odense University Hospital
- Azonosító
- NCT07634263
- A regiszteradat frissítve
- 2026. október 23.
- Eredeti leírás
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing. Home-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood. This study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment. The findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.A teljes eredeti leírásKevesebb
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing. Home-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood. This study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment. The findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.
Bevonási feltételek: >=18 years old; diagnosed Multiple Myeloma or acute leukemia, and recieving treatment with either Daratumumab or Cytarabine.
Kizáró feltételek: Dementia, psychotic disorders, or other cognitive impairments limiting participation.